ALSO IN THIS MONTH'S ISSUE

  • What Does The Trump Pivot Mean For Healthcare?
    What Does The Trump Pivot Mean For Healthcare?

    Frustrated with congressional Republican inaction on major pieces of his agenda, President Trump cut deals with Democrats on a short-term increase in the debt ceiling and funding the government. Then to the surprise and consternation of his base, Trump agreed to work on a deal to extend DACA, a Democratic priority. But what does Trump’s new interest in working with Democrats mean for healthcare policy-making? That is not yet clear.

  • A Name Change — And More — For A Biotech
    A Name Change — And More — For A Biotech

    When Maria Fardis, Ph.D., MBA, joined Lion Biotechnologies as CEO, she knew “The word ‘Lion’ didn’t really define us as a company or the advancements we had made with our TIL technology.” So, nine months into her tenure, Fardis and her team began the process of changing the company name to Iovance.

  • Can AI Deliver Faster, Better Drug Development?
    Can AI Deliver Faster, Better Drug Development?

    As the cost of developing new medicines continues to rise, more pharmaceutical companies are looking at how artificial intelligence (AI) can help in drug development. But there are some hurdles to overcome before its full potential is reached.

  • How Moving Up Through The Ranks Can Shape A Biotech CEO
    How Moving Up Through The Ranks Can Shape A Biotech CEO

    All CEOs of small, publicly traded biotechs are required to wear many hats in the office every day. That’s why having a leader with a diverse background and experience in a variety of functional areas is an asset. Here we look at some of the various areas of expertise that can help create a more diverse C-suite executive.

  • Why South Korea Is The Hottest Growth Spot For Clinical Trials
    Why South Korea Is The Hottest Growth Spot For Clinical Trials

    “The Korean pharmaceutical industry has been accelerating investments in open innovation and focusing on R&D for entry into overseas markets,” says Deborah Chee, president, Korean National Enterprise for Clinical Trials.

More from this month's issue

BEYOND THE PRINTED PAGE

  • Daniel Skovronsky – From Grad Student, To CEO, To Big Pharma
    Daniel Skovronsky – From Grad Student, To CEO, To Big Pharma

    Prior to joining Lilly as SVP of clinical and product development, Daniel Skovronsky, M.D., Ph.D. was CEO of Avid Radiopharmaceuticals — a company he founded while still a graduate student. This article is a prequel to the upcoming feature in our November issue that explores how he built a $300 million company.

  • Does The Biopharmaceutical Industry Need To Broaden Its Horizons?
    Does The Biopharmaceutical Industry Need To Broaden Its Horizons?

    When I interviewed Axovant Sciences CEO David Hung, one of the questions posed was sparked by our discussion of his experience at Pro-Duct Health and his invention of a microcatheter for early detection of ductal breast cancer in women. As he explained his medical device invention, Hung commented, “I don’t want to be just medicines, or just devices, or anything like that.”

  • What Might Be The Best Predictor Of Future Performance At Axovant Sciences?
    What Might Be The Best Predictor Of Future Performance At Axovant Sciences?

    Chief Editor Rob Wright recently conducted an in-person interview with David Hung, formerly of Medivation and current  CEO of Axovant Sciences. Though many may credit the FDA’s approval of Medivation’s Xtandi (enzalutamide) as being the primary driver behind Hung’s rise, Wright argues that there are a number of other predictors that should be evaluated when anticipating future success.

  • Allergan’s Brent Saunders Shares A Social Contract Secret
    Allergan’s Brent Saunders Shares A Social Contract Secret

    Don't miss this free (all-access) sneak peek of our upcoming September feature article on how Brent Saunders built Allergan’s social contract, a document that may likely define his biopharma legacy. “Over time, as people evaluate my leadership in the role, I hope it is not limited to the social contract," he says.

More beyond the printed page articles

WEB-EXCLUSIVE EDITORIAL

  • U.S. CEOs See Greater Willingness To Use Artificial Intelligence: KPMG Survey
    U.S. CEOs See Greater Willingness To Use Artificial Intelligence: KPMG Survey

    According to KPMG’s 2017 CEO Outlook, more than two-thirds of U.S. life sciences CEOs say their organizations are ready to adopt advanced artificial intelligence (AI) technology, but they acknowledge there are barriers to implementing it.

  • When The Goal Is To Be (Bio)similar, What Does Differentiation Mean?
    When The Goal Is To Be (Bio)similar, What Does Differentiation Mean?

    As concerns about the cost of medicines reach a fever pitch, innovators are looking to leverage a promising advancement to help address the fundamental need for sustainable healthcare in the U.S. — biosimilars.

  • Biosimilar Regulatory Best Practices: Don’t Fear Exploration
    Biosimilar Regulatory Best Practices: Don’t Fear Exploration

    In the first of this two-part article, Sandoz's Cindy Cao shares lessons learned from working with the FDA and reveals that there is still a lot of room for exploration and innovation in biosimilar development.

  • Investors Drumming Up New Solutions To The Industry’s Real Estate Crunch
    Investors Drumming Up New Solutions To The Industry’s Real Estate Crunch

    Investors are recognizing life sciences real estate as a valuable specialty asset class. In fact, it’s a trend gaining momentum as major real estate investment trusts (REITs) and entrepreneurial investors alike create new homes for life sciences activities.

  • 5 Steps To Set Effective Goals For A Life Science Consultant
    5 Steps To Set Effective Goals For A Life Science Consultant

    There is a trend within the pharmaceutical, biopharmaceutical, medical device, and vaccine industries to hire more consultants, leading to a staffing ratio that can be up to 50 percent consultants to staff for small to large capital projects.

  • Why Are We Still Talking About Study Startup?
    Why Are We Still Talking About Study Startup?

    Organizations are always looking to optimize the startup process so they can bring products to market quicker — getting potentially lifesaving drugs into the hands of patients is the primary goal — while also reducing each study budget so more products can be pursued to help other patient groups.

  • Boehringer Ingelheim And The Two Sides Of Biologics Outsourcing
    Boehringer Ingelheim And The Two Sides Of Biologics Outsourcing

    Jens Vogel, President & CEO, BI Fremont Inc., can’t help seeing two sides to most everything associated with the development and manufacturing of biologics. For example, he says we are in an era that at the same time can be dubbed “Death of the Blockbuster” and “Return of the Blockbuster.”

  • Commissioner Gottlieb, CAR T-Cells, & The Future Of Rare Disease Therapies
    Commissioner Gottlieb, CAR T-Cells, & The Future Of Rare Disease Therapies

    FDA Commissioner Scott Gottlieb has taken the wheel at an exciting time, when insights from genomics are starting to come to fruition and promising new therapies based on new technologies are being developed. This article explores some of the policy changes happening now in the regulatory rare disease space — and shifts we expect to see in the future — as the FDA’s leadership team implements these changes at the agency.

More web-exclusive editorial

OCTOBER 2017 DIGITAL EDITION

2017 CMO & CRO AWARDS EDITIONS

   

@LIFESCILEADER1

 EVENTS

BioNetwork 2017 October 23 - 25, 2017
Laguna Niguel, CA
Biosimilars Conference October 24 - 25, 2017
Bethesda,, MD
Data Integrity: Why Not Identifying Repeat Defects In Your Data Is Killing Your Performance November 6, 2017
1:00 PM - 2:00 PM EDT
Duration:  60 Minutes
Price:  $299 – Includes Bonus handouts
Adverse Event Reporting: Avoiding Common Pitfalls November 7, 2017
1pm-2:30pm EST, Online Training
Price:  $299 - Includes Bonus Handouts!
More events....